September 12, 1978 
Dr. Joseph G. Perpich 
Building 1, Room 137 
National Institutes of Health 
Bethesda, Maryland 20014 
Dear Dr. Perpich: 
This note is in response to your August 7, 1978, request to 
me for comment on the proposed revised guidelines for 
Recombinant DNA research. 
Because the large scale industrial use of recombinant technology 
may pose unique risks and problems not encountered in the 
research laboratory, the membership should include at least 
one scientist from a regulatory agency, who is familiar with 
manufacturing processes and potential hazards. This is of 
particular importance since the NIH guidelines have not yet 
been extended to the private sector. 
Rosa M. Gryder, Ph.D. 
Staff Science Advisor 
Office of Health Affairs/FDA 
[A-124] 
